Ganstigmine (CHF 2819).
D000109:Acetylcholine / Q000378:metabolism; D000328:Adult; D000470:Alkaloids / Q000009:adverse effects / Q000627:therapeutic use*; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D000818:Animals; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D003072:Cognition Disorders / Q000188:drug therapy / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D051381:Rats
D000470:Alkaloids; D002219:Carbamates; D002800:Cholinesterase Inhibitors; D000109:Acetylcholine; C447079:ganstigmine